Wounded Marine and His Family to Receive Life-Changing Home Makeover on Military Makeover with Montel®
Full makeover will be realized between June 10th to June 22nd.
The reveal of the home makeover will be filmed on June 22nd.
KING, N.C. , May 28, 2025 /PRNewswire/ -- Military Makeover with Montel® along with Official Non-Profit Partner, Purple Heart Homes, proudly announces its upcoming season spotlighting the remarkable story of U.S. Marine Corps veteran Sean Reeves and his family. Coming to Lifetime TV this summer, this season will follow an inspiring path of bravery, dedication, and recovery, culminating in a well-earned home makeover for a selfless family. Sean's courageous service and sacrifice were recognized with many military decorations, such as the Purple Heart, Combat Action Ribbon, Presidential Unit Citation, NATO Medal ISAF Afghanistan, and the Afghanistan Campaign Ribbon, among others.
Driven by the September 11th attacks, Sean Reeves enlisted in the United States Marine Corps upon his 2008 high school graduation. He served as an infantry rifleman (0311) with the First Battalion, Second Marines and was deployed to Afghanistan in 2010. During Operation Northern Penetration, Mr. Reeves sustained a traumatic brain injury (TBI) and three gunshot wounds resulting from an improvised explosive device (IED) detonation and subsequent ambush. Despite these severe injuries, he continued his military service until his medical retirement in 2011.
Presently, Mr. Reeves is employed as a Care Coordinator at Veterans Bridge Home, providing support to veterans and their families as they navigate challenging transitions. Notwithstanding persistent chronic pain, cognitive impairments, post-traumatic stress disorder (PTSD), and having achieved remission from non-Hodgkin lymphoma, he remains a dedicated advocate and an essential source of support within the veteran community.
"The story of the Reeves family is one of resilience and commitment to community," said Nicole Oropesa, President of BrandStar Entertainment. "Through Military Makeover with Montel, we are honored to recognize and uplift a family who truly embodies the heart of service to their fellow veterans."
With the help of generous partners and the King, NC community, alongside Co-Host Art Edmonds and Designer Jennifer Bertrand, Military Makeover with Montel® will renovate the Reeves family home to reflect the care, accessibility, and comfort they deserve.
To volunteer, click here.
Military Makeover with Montel: Military Makeover with Montel® is an award-winning reality TV series dedicated to transforming the homes and lives of military families across the country. Hosted by Veteran, Author and TV Personality Montel Williams, alongside Co-Host Art Edmonds and Designer Jennifer Bertrand, the show brings together businesses, non-profits, and local communities to create lasting change for those who've served. Airing on Lifetime® and the American Forces Network, Military Makeover is more than a renovation show—it's a powerful mission where help, healing, and hope truly start at home. For more information, visit www.MilitaryMakeover.tv
Purple Heart Homes: Purple Heart Homes is a 501(c)3 nonprofit organization founded by John Gallina and the late Dale Beatty, two Iraq combat-wounded Veterans who started a mission to provide housing solutions for Service-Connected Disabled Veterans and their families. Driven by the belief that no Veteran should be left behind, Purple Heart Homes, together with the community, is committed to ensuring quality of life solutions for Disabled American Veterans from all eras. Purple Heart Homes – Improving Veterans' Lives One Home at a Time.For more information, visit www.phhusa.org and follow us on X @PHHTweet and Facebook and Instagram @PurpleHeartHomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/wounded-marine-and-his-family-to-receive-life-changing-home-makeover-on-military-makeover-with-montel-302467485.html
SOURCE Military Makeover with Montel
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Israeli forces kill 63 Palestinian in Gaza within hours of ‘humanitarian pause'
The Israeli military killed at least 63 people across Gaza just hours after declaring daily 'pauses' in operations to facilitate the passage of humanitarian aid, health officials said. The military said on Sunday it would suspend operations daily from 10am until 8pm in parts of central and northern Gaza, including al-Mawasi, Deir el-Balah and Gaza City, and promised to open aid corridors from 6am to 11pm to let in food and medical supplies. However, within hours of the so-called 'humanitarian pause' taking effect, Israeli forces resumed air raids. One reported strike targeted a bakery in an area designated as a 'safe zone', according to Al Jazeera. The humanitarian crisis continued to worsen. Health officials reported six more deaths, including of two children, from starvation in the past 24 hours, taking the total to 133. Among the latest to succumb was five-month-old Zainab Abu Haleeb, who died of malnutrition at the Nasser Hospital. 'Three months inside the hospital and this is what I get in return, that she is dead,' her mother Israa Abu Haleeb told Al Jazeera. The World Food Programme said one in three people in Gaza had gone days without food and about half a million were experiencing famine-like conditions. More than 20 per cent of pregnant and breastfeeding women were malnourished, according to the World Health Organization. Israel maintains that it is working to improve aid access and denies that famine exists in Gaza. But aid organisations say the situation is catastrophic, with a quarter of the population at risk of acute malnutrition. UN officials say the crisis won't ease unless Israel speeds up the movement of aid convoys through its checkpoints. A top UN official said last week Palestinians were beginning to resemble 'walking corpses'. Philippe Lazzarini, head of the UN agency for Palestinian refugees, Unrwa, said humanitarian workers were encountering children who were 'emaciated, weak and at high risk of dying' without immediate intervention. 'Families are no longer coping. They're breaking down, unable to survive,' Mr Lazzarini said. 'Their existence is threatened.' Israel has severely limited the flow of food and humanitarian aid into Gaza, allowing only a small number of trucks to enter each day after enforcing an 11-week total blockade earlier this year. UN officials warn the current level of aid is merely a drop in the ocean compared to the scale of need. The Israeli military intercepted an aid ship bound for Gaza that aimed to breach the blockade on the Palestinian territory, detaining 21 international activists and journalists and confiscating all cargo, including baby formula, food, and medicine, according to the Freedom Flotilla Coalition on Sunday. The group said Israeli forces 'violently intercepted' their vessel, Handala, in international waters around 40 nautical miles off the coast of Gaza, cutting off cameras and communication shortly before midnight on Saturday. 'All cargo was non-military, civilian and intended for direct distribution to a population facing deliberate starvation and medical collapse under Israel's illegal blockade,'' the group said in a statement. It was the second ship operated by the coalition that Israeli forces prevented in recent months from delivering aid to Gaza. It was reported on Sunday that Jordan and the UAE had begun airdropping aid into the besieged Palestinian territory. But Mr Lazzarini said 'airdrops will not reverse the deepening starvation'. 'They are expensive, inefficient and can even kill starving civilians. It is a distraction & smokescreen,' he said in an X post. 'A manmade hunger can only be addressed by political will. Lift the siege, open the gates and guarantee safe movements with dignified access to people in need. Israel's war on Gaza has killed nearly 60,000 Palestinians, injured over 144,000, and left most of the densely populated coastal territory in ruins and the majority of its 2.2 million people homeless and starving. Israel launched the war in October 2023 after nearly 1,200 Israelis were killed and 251 taken hostage during a Hamas attack.
Business Wire
2 hours ago
- Business Wire
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology
LYON, France--(BUSINESS WIRE)--Regulatory News: We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT Pharma's growth on bringing the potential first microbiome-based therapy to market in Europe. MaaT Pharma (EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that it has secured a €37.5 million, 4-tranche financing from the European Investment Bank (EIB). The financing will support the advancement of its late-stage hemato-oncology clinical programs including the lead-asset Xervyteg ®, recently partnered with Clinigen in Europe, and currently under regulatory review by the European Medicines Agency (EMA) for the treatment of acute Graft-versus-Host Disease (aGvHD) and the second drug candidate, MaaT033, currently being evaluated in a Phase 2b randomized controlled trial in improving survival for patients receiving allogeneic stem cell transplants. With robust cGMP manufacturing, proprietary therapies, and a development platform, MaaT Pharma is a global leader in microbiome-based oncology, pioneering full-ecosystem therapies to improve survival in oncology. Since completing enrollment in the ARES trial for Xervyteg ® (MaaT013) in October 2024, MaaT Pharma has steadily advanced its roadmap, reporting topline results in January 2025, submitting the Marketing Authorization Application with the European Medicines Agency in June 2025, and signing an exclusive agreement for marketing and distribution in Europe with Clinigen in July 2025. The €37.5 million financing from the EIB follows a rigorous due diligence process by the EIB and further confirms MaaT Pharma's innovation, strategic vision and operational maturity. This funding is part of a global financial strategy to support the Company's development that combines various non-dilutive and dilutive sources to best preserve shareholder value. Eric Soyer, Chief Financial Officer, MaaT Pharma, said: 'We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT Pharma's growth on bringing the potential first microbiome-based therapy to market in Europe. Each operational and financing step strengthens our track record. Following the regulatory submission to the EMA for Xervyteg ® (MaaT013) and our recent partnership with Clinigen for its commercialization, the EIB financing represents another step in reinforcing the Company's financial position. As previously announced, MaaT Pharma intends to fund its plans and development programs while preserving shareholder value in the best manner possible with a mix of non-dilutive and dilutive financial sources, and the recent announcements of both partnership financing with the Clinigen agreement and debt financing with the EIB agreement, are benchmarks to reflect that strategy.' Summary of the main terms and conditions of the Loan and Warrants The loan would be available in four (4) tranches, respectively of €3.5 million for Tranche A, €6.0 million for Tranche B, €8.0 million for Tranche C, and €20.0 million for Tranche D, each tranche with Warrants attached. Disbursement of Tranches 2 to 4 are subject to operational and financing conditions. All Tranches are redeemable after a grace period of 4 years from the date of drawing, with reimbursement over a period of 2 years (Tranche A, B and C, i.e. a maturity of 6 years) to 4 years (Tranche D, i.e. a maturity of 8 years). Each tranche will bear interests at 7%, it being provided that some interests will be deferred and paid at maturity and for Tranche C and Tranche D part of the interest will be paid quarterly. MaaT Pharma will issue warrants to the benefit of EIB at the time of (and subject to) disbursement of each tranche in a number depending, for each relevant tranche, on the amount of the relevant tranche and the average price per share paid by investors in the context of equity injection made prior to disbursement of the relevant tranche (except for tranche A where the average price per share over the last trading days preceding the date of execution of the financing agreement). Each warrant will give right to subscribe to one share at a price per warrant equal to 99% of the average price over a period of 5 trading days preceding the issuance of each Warrant. The Warrants may be exercised at any time following maturity of Tranche A. The Warrants will have a 20-year term. EIB and MaaT Pharma have also agreed on (i) a put option to the benefit of EIB under which MaaT Pharma undertook to acquire from EIB all or part of the Warrants upon occurrence of certain events and (ii) a call option to the benefit of MaaT Pharma under which EIB undertook to sell all its Warrants, upon occurrence of a public tender offer over the securities issued by MaaT Pharma. The Warrants are not transferable, except to affiliates of EIB or except in case of occurrence of certain events (including maturity date of Tranche D). In case of transfer of Warrants to third party, MaaT Pharma shall benefit from a preemptive right to acquire the Warrants first. MaaT Pharma was assisted in this transaction by Mr. Eric Briole and by Van Lanschot Kempen as Financial Advisors and McDermott Will & Emery as Legal Advisor. About EIB The European Investment Bank (EIB), whose shareholders are the Member States of the European Union (EU), is the EU's long-term financing institution. Across eight major priorities, we support investments in climate action and the environment, digital transition and technological innovation, security and defense, cohesion, agriculture and the bioeconomy, social infrastructure, capital markets union, and a stronger Europe in a more peaceful and prosperous world. In 2024, the EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing in support of more than 900 projects in Europe and worldwide. In France, the EIB Group signed over a hundred operations in 2024 for a total amount of €12.6 billion. Nearly 60% of the EIB Group's annual financing supports projects contributing to climate change mitigation and adaptation, as well as the creation of a healthier environment. About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 'target,' 'believe,' 'expect,' 'aim', 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.
Business Wire
2 hours ago
- Business Wire
Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal® in Saudi Arabia
PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth® - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, obtains marketing authorization (MA) and reimbursement status for Sibnayal® (a fixed combination of potassium citrate and potassium bicarbonate) in the Kingdom of Saudi Arabia (KSA). Marketing authorization for Sibnayal® (ADV7103) in distal Renal Tubular Acidosis (dRTA) in KSA has been granted, based on the European registration dossier. Furthermore, Saudi authorities have agreed a reimbursement rate in line with the best European pricing. This achievment results of a close collaboration between Advicenne and its local partner, Taïba Healthcare, a leading distributor of pharmaceutical products in the Gulf region. Advicenne will act as the marketing authorization holder, while Taïba Healthcare will manage local marketing activities. The incidence of dRTA is higher in Gulf countries than in Europe or the United States, and prevalence in KSA could be estimated around 600 to 800 patients. Sibnayal® is already prescribed through early access programs in several Gulf countries outside Saudi Arabia. This milestone paves the way for registrations in GCC countries where the application is filed. Didier Laurens, CEO of Advicenne, declared: 'I am particularly proud of this important achievement and wish to congratulate both Advicenne and Taïba Healthcare teams, whose efforts were instrumental in informing and convincing the Saudi health authorities. The reimbursement obtained, comparable to the highest levels recorded in Europe, further attests to the significant therapeutic value of Sibnayal® in a region with one of the highest prevalence rates of dRTA worldwide.' About Advicenne Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information, see: Disclaimer This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2024 Universal Registration Document filed with the French financial market authority on April 29, 2025 (a copy of which is available on and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.
